Edition:
United States

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

48.75USD
20 Sep 2018
Change (% chg)

$1.20 (+2.52%)
Prev Close
$47.55
Open
$46.74
Day's High
$48.98
Day's Low
$46.74
Volume
34,237
Avg. Vol
34,088
52-wk High
$68.91
52-wk Low
$25.58

Select another date:

Thu, Jun 21 2018

Photo

Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

INTERVIEW-Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel, June 21 Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101

* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)

BRIEF-UroGen Pharma Reports Q1 Loss Per Share Of $0.88

* UROGEN PHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

Select another date: